Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Zhiyi Lan,Nafees Ahmad,Parvaneh Baghaei,Linda Barkane,Andrea Benedetti,Sarah K Brode,James C M Brust,Jonathon R Campbell,Vicky Wai Lai Chang,Dennis Falzon,Lorenzo Guglielmetti,Petros Isaakidis,Russell R Kempker,Maia Kipiani,Liga Kuksa,Christoph Lange,Rafael Laniado-Laborín,Payam Nahid,Denise Rodrigues,Rupak Singla,Zarir F Udwadia,Dick Menzies,Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017,N Ahmad,P Baghaei,L Barkane,A Benedetti,S K Brode,Jcm Brust,J R Campbell,Vwl Chang,D Falzon,L Guglielmetti,P Isaakidis,R R Kempker,M Kipiani,L Kuksa,Z Lan,C Lange,R Laniado-Laborín,P Nahid,D Rodrigues,R Singla,Z F Udwadia,D Menzies
DOI: https://doi.org/10.1016/S2213-2600(20)30047-3
Abstract:Background: Treatment of multidrug-resistant tuberculosis requires long-term therapy with a combination of multiple second-line drugs. These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead to death. Our aim was to estimate the absolute and relative frequency of adverse events associated with different tuberculosis drugs to provide useful information for clinicians and tuberculosis programmes in selecting optimal treatment regimens. Methods: We did a meta-analysis using individual-level patient data that were obtained from studies that reported adverse events that resulted in permanent discontinuation of anti-tuberculosis medications. We used a database created for our previous meta-analysis of multidrug-resistant tuberculosis treatment and outcomes, for which we did a systematic review of literature published between Jan 1, 2009, and Aug 31, 2015 (updated April 15, 2016), and requested individual patient-level information from authors. We also considered for this analysis studies contributing patient-level data in response to a public call made by WHO in 2018. Meta-analysis for proportions and arm-based network meta-analysis were done to estimate the incidence of adverse events for each tuberculosis drug. Findings: 58 studies were identified, including 50 studies from the updated individual patient data meta-analysis for multidrug-resistant tuberculosis treatment. 35 of these studies, with 9178 patients, were included in our analysis. Using meta-analysis of proportions, drugs with low risks of adverse event occurrence leading to permanent discontinuation included levofloxacin (1·3% [95% CI 0·3-5·0]), moxifloxacin (2·9% [1·6-5·0]), bedaquiline (1·7% [0·7-4·2]), and clofazimine (1·6% [0·5-5·3]). Relatively high incidence of adverse events leading to permanent discontinuation was seen with three second-line injectable drugs (amikacin: 10·2% [6·3-16·0]; kanamycin: 7·5% [4·6-11·9]; capreomycin: 8·2% [6·3-10·7]), aminosalicylic acid (11·6% [7·1-18·3]), and linezolid (14·1% [9·9-19·6]). Risk of bias in selection of studies was judged to be low because there were no important differences between included and excluded studies. Variability between studies was significant for most outcomes analysed. Interpretation: Fluoroquinolones, clofazimine, and bedaquiline had the lowest incidence of adverse events leading to permanent drug discontinuation, whereas second-line injectable drugs, aminosalicylic acid, and linezolid had the highest incidence. These results suggest that close monitoring of adverse events is important for patients being treated for multidrug-resistant tuberculosis. Our results also underscore the urgent need for safer and better-tolerated drugs to reduce morbidity from treatment itself for patients with multidrug-resistant tuberculosis. Funding: Canadian Institutes of Health Research, Centers for Disease Control and Prevention (USA), American Thoracic Society, European Respiratory Society, and Infectious Diseases Society of America.